Safety and response with nivolumab (Anti-PD-1; BMS-936558, ONO-4538) plus erlotinib in patients (Pts) with epidermal growth factor receptor mutant (EGFR MT) advanced non-small cell lung cancer (NSCLC) Meeting Abstract


Authors: Gettinger, S.; Chow, L. Q.; Borghaei, H.; Shen, Y.; Harbison, C.; Chen, A. C.; Rizvi, N. A.
Abstract Title: Safety and response with nivolumab (Anti-PD-1; BMS-936558, ONO-4538) plus erlotinib in patients (Pts) with epidermal growth factor receptor mutant (EGFR MT) advanced non-small cell lung cancer (NSCLC)
Meeting Title: 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology
Journal Title: International Journal of Radiation Oncology, Biology, Physics
Volume: 90
Issue: 5 Suppl.
Meeting Dates: 2014 Oct 30-Nov 1
Meeting Location: Chicago, IL
ISSN: 0360-3016
Publisher: Elsevier Inc.  
Date Published: 2014-11-15
Start Page: S34
End Page: S35
Language: English
ACCESSION: WOS:000346413500073
PROVIDER: wos
DOI: 10.1016/j.ijrobp.2014.08.210
Notes: Meeting Abstract: 171 -- Chicago Multidisciplinary Symposium in Thoracic Oncology -- OCT 30-NOV 01, 2014 -- Chicago, IL -- 5 -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Naiyer A Rizvi
    166 Rizvi